Speaker(s): 

Jason Batten, MD MA, University of California - has nothing to disclose.
 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 
  • Recognize how routine clinical language (e.g., "treatable") can generate unwarranted inferences and false encouragement to pursue treatment for critically ill patients and their surrogates.
  • Compare and contrast recommended decision-making approaches for limiting life-sustaining treatments (e.g., shared decision-making, institutional processes) with clinician-reported alternate approaches (e.g., not offering or not mentioning treatments).
  • Analyze how clinical decision-making norms (e.g., default pathways, ethical thresholds) shape everyday dynamics surrounding the use of life-sustaining treatments, and how they might be modified to reduce the use of non-beneficial treatments near the end of life.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Michelle Meyer, PhD, JD, HEC-C; Kaylee Kachurka, PA-C; Linda Page, BS, RRT; Brian Simpkins, PharmD, BCPS; Greg Burke, MD; Sharon Gray, BSN, RN, HEC-C; Erin Hall, PsyD, MSCP; Daniel Hoegen, MSW, LSW, HEC-C; Elizabeth McDonald, RDN; F. Daniel Davis, PhD, HEC-C; Max Kramer, PhD; Christopher Chabris, PhD; John Pagnotto, DO, MBA, SFHM; Ronald Napikoski, MBA, RRT, RPFT, and Anne Kasper, MS, MA, LPC, BCC have no identified disclosures. 
 
CE Committee Member/Content Reviewers have nothing to disclose. 
 
Any/All relevant financial relationships have been mitigated. 
 

Content Disclosure: 

This presentation/content is HIPAA compliant. 
 

Commercial Support for this Session

None
Session date: 
06/03/2026 - 4:00pm to 5:00pm EDT
Location: 
Virtual via Microsoft Teams
PA
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AAPA Category I CME
  • 1.00 ACPE
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation Credit
Please login or register to take this course.